SEARCH

SEARCH BY CITATION

References

  • 1
    Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 11381180.
  • 2
    American Thoracic Society; Infectious Disease Society of North America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388416.
  • 3
    Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 38543862.
  • 4
    Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007; 51: 35683573.
  • 5
    El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 2004; 39: 474480.
  • 6
    El-Solh AA, Pietrantoni C, Bhat A et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003; 167: 16501654.
  • 7
    Carratala J, Mykietiuk A, Fernandez-Sabe N et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007; 167: 13931399.
  • 8
    Garb JL, Brown RB, Garb JR, Tuthill RW. Differences in etiology of pneumonias in nursing home and community patients. JAMA 1978; 240: 21692172.
  • 9
    Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001; 18: 362368.
  • 10
    Marrie TJ, Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc 1997; 45: 5055.
  • 11
    Meehan TP, Chua-Reyes JM, Tate J et al. Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 2000; 117: 13781385.
  • 12
    Naughton BJ, Mylotte JM, Ramadan F, Karuza J, Priore RL. Antibiotic use, hospital admissions, and mortality before and after implementing guidelines for nursing home-acquired pneumonia. J Am Geriatr Soc 2001; 49: 10201024.
  • 13
    Shindo Y, Sato S, Maruyama E et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009; 135: 633640.
  • 14
    Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008; 168: 22052210.
  • 15
    Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009; 150: 1926.
  • 16
    Webster D, Chui L, Tyrrell GJ, Marrie TJ. Health care-associated Staphylococcus aureus pneumonia. Can J Infect Dis Med Microbiol 2007; 18: 181188.
  • 17
    Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008; 134: 963968.
  • 18
    Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50: 202209.
  • 19
    Ewig S, Torres A, Angeles Marcos M et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002; 20: 12541262.
  • 20
    Korppi M. Mixed microbial aetiology of community-acquired pneumonia in children. APMIS 2002; 110: 515522.
  • 21
    Gutierrez F, Masia M, Rodriguez JC et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005; 24: 377383.
  • 22
    de Roux A, Marcos MA, Garcia E et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004; 125: 13431351.
  • 23
    Angeles Marcos M, Camps M, Pumarola T et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006; 11: 351359.
  • 24
    Lauderdale TL, Chang FY, Ben RJ et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005; 99: 10791086.
  • 25
    Wattanathum A, Chaoprasong C, Nunthapisud P et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 2003; 123: 15121519.
  • 26
    Saito A, Kohno S, Matsushima T et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother 2006; 12: 6369.
  • 27
    Jennings LC, Anderson TP, Beynon KA et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63: 4248.
  • 28
    Song JH, Oh WS, Kang CI et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31: 107114.
  • 29
    de Roux A, Ewig S, Garcia E et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006; 27: 795800.
  • 30
    Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) – United States, May–August 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 10711074.
  • 31
    Almirall J, Bolibar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757763.
  • 32
    Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998; 20: 885900.
  • 33
    Blasi F, Cosentini R, Raccanelli R et al. Emerging pathogens of community-acquired pneumonia: a two-year prospective study. J Chemother 1995; 7 (suppl 4): 115116.
  • 34
    Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543547.
  • 35
    Brandenburg JA, Marrie TJ, Coley CM et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15: 638646.
  • 36
    El Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163 (3 Pt 1): 645651.
  • 37
    Ginesu F, Pirina P, Deiola G, Ostera S, Mele S, Fois AG. Etiology and therapy of community-acquired pneumonia. J Chemother 1997; 9: 285292.
  • 38
    Gomez J, Banos V, Ruiz GJ et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15: 556560.
  • 39
    Gowardman J, Trent L. Severe community acquired pneumonia: a one-year analysis in a tertiary referral intensive care unit. N Z Med J 2000; 113: 161164.
  • 40
    Hedlund J, Kalin M, Ortqvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. Scand J Infect Dis 1997; 29: 387392.
  • 41
    Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997; 52: 1721.
  • 42
    Jokinen C, Heiskanen L, Juvonen H et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis 2001; 32: 11411154.
  • 43
    Jones RN, Croco MA, Kugler KC, Pfaller MA, Beach ML. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 2000; 37: 115125.
  • 44
    Leroy O, Vandenbussche C, Coffinier C et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med 1997; 156: 19221929.
  • 45
    Leroy O, Bosquet C, Vandenbussche C et al. Community-acquired pneumonia in the intensive care unit: epidemiological and prognosis data in older people. J Am Geriatr Soc 1999; 47: 539546.
  • 46
    Logroscino CD, Penza O, Locicero S et al. Community-acquired pneumonia in adults: a multicentric observational AIPO study. Monaldi Arch Chest Dis 1999; 54: 1117.
  • 47
    Lorente ML, Falguera M, Nogues A, Gonzalez AR, Merino MT, Caballero MR. Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: a prospective clinical study. Thorax 2000; 55: 133137.
  • 48
    Lim WS, Macfarlane JT, Boswell TC et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296301.
  • 49
    Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508515.
  • 50
    Meijer A, Dagnelie CF, de Jong JC et al. Low prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae among patients with symptoms of respiratory tract infections in Dutch general practices. Eur J Epidemiol 2000; 16: 10991106.
  • 51
    Menendez R, Cordoba J, de La CP et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999; 159: 18681873.
  • 52
    Michetti G, Pugliese C, Bamberga M et al. Community-acquired pneumonia: is there difference in etiology between hospitalized and out-patients? Minerva Med 1995; 86: 341351.
  • 53
    Olaechea PM, Quintana JM, Gallardo MS, Insausti J, Maravi E, Alvarez B. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission. Intensive Care Med 1996; 22: 12941300.
  • 54
    Ruiz M, Ewig S, Marcos MA et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397405.
  • 55
    Socan M, Marinic-Fiser N, Kraigher A, Kotnik A, Logar M. Microbial aetiology of community-acquired pneumonia in hospitalised patients. Eur J Clin Microbiol Infect Dis 1999; 18: 777782.
  • 56
    Sopena N, Sabria M, Pedro-Botet ML et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999; 18: 852858.
  • 57
    Steinhoff D, Lode H, Ruckdeschel G et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996; 22: 958964.
  • 58
    Garcia-Vidal C, Carratala J, Fernandez-Sabe N et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect 2009; 15: 10331038.
  • 59
    Berglund C, Molling P, Sjoberg L, Soderquist B. Predominance of staphylococcal cassette chromosome mec (SCCmec) type IV among methicillin-resistant Staphylococcus aureus (MRSA) in a Swedish county and presence of unknown SCCmec types with Panton-Valentine leukocidin genes. Clin Microbiol Infect 2005; 11: 447456.
  • 60
    Gillet Y, Issartel B, Vanhems P et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: 753759.
  • 61
    Hageman JC, Uyeki TM, Francis JS et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 2006; 12: 894899.
  • 62
    Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 11281132.
  • 63
    Davis SL, Perri MB, Donabedian SM et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007; 45: 17051711.
  • 64
    van der HW, Dijkstra F, Schimmer B et al. Q fever in the Netherlands: an update on the epidemiology and control measures. Euro Surveill 2010; 15: 14.
  • 65
    Creer DD, Dilworth JP, Gillespie SH et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax 2006; 61: 7579.
  • 66
    Flamaing J, Engelmann I, Joosten E, Van RM, Verhaegen J, Peetermans WE. Viral lower respiratory tract infection in the elderly: a prospective in-hospital study. Eur J Clin Microbiol Infect Dis 2003; 22: 720725.
  • 67
    Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134: 11411148.
  • 68
    Beigel JH, Farrar J, Han AM et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 13741385.
  • 69
    Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005; 11: 201209.
  • 70
    Miedzinski L. Community-acquired pneumonia: new facets of an old disease – Hantavirus pulmonary syndrome. Respir Care Clin N Am 2005; 11: 4558.
  • 71
    Patrick DM, Petric M, Skowronski DM et al. An outbreak of human Coronavirus OC43 infection and serological cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol 2006; 17: 330336.
  • 72
    Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 19671976.
  • 73
    Chowell G, Bertozzi SM, Colchero MA et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361: 674679.
  • 74
    Gutierrez F, Masia M, Mirete C et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006; 53: 166174.
  • 75
    Ingarfield SL, Celenza A, Jacobs IG, Riley TV. The bacteriology of pneumonia diagnosed in Western Australian emergency departments. Epidemiol Infect 2007; 135: 13761383.
  • 76
    Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 15421548.
  • 77
    Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 4046.
  • 78
    Alamoudi OS. Bacterial infection and risk factors in outpatients with acute exacerbation of chronic obstructive pulmonary disease: a 2-year prospective study. Respirology 2007; 12: 283287.
  • 79
    McManus TE, Marley AM, Baxter N et al. Respiratory viral infection in exacerbations of COPD. Respir Med 2008; 102: 15751580.
  • 80
    Roche N, Kouassi B, Rabbat A, Mounedji A, Lorut C, Huchon G. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum. Respiration 2007; 74: 1925.
  • 81
    Hutchinson AF, Ghimire AK, Thompson MA et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med 2007; 101: 24722481.
  • 82
    Diederen BM, van der Valk PD, Kluytmans JA, Peeters MF, Hendrix R. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 30: 240244.
  • 83
    Ko FW, Ip M, Chan PK et al. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest 2007; 131: 4452.
  • 84
    Monso E, Garcia-Aymerich J, Soler N et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003; 131: 799804.
  • 85
    Murphy TF, Brauer AL, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853860.
  • 86
    Lieberman D, Lieberman D, Gelfer Y et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 12641270.
  • 87
    Buscho RO, Saxtan D, Shultz PS, Finch E, Mufson MA. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978; 137: 377383.
  • 88
    Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465471.
  • 89
    Angrill J, Agusti C, de CR et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 1519.
  • 90
    Ho PL, Chan KN, Ip MS et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 15941598.
  • 91
    Boldy DA, Skidmore SJ, Ayres JG. Acute bronchitis in the community: clinical features, infective factors, changes in pulmonary function and bronchial reactivity to histamine. Respir Med 1990; 84: 377385.
  • 92
    Everett MT. Major chest infection managed at home. Practitioner 1983; 227: 17431754.
  • 93
    Fransen H, Wolontis S. Infections with viruses, Mycoplasma pneumoniae and bacteria in acute respiratory illness. A study of hospitalized patients, patients treated at home, and healthy subjects. Scand J Infect Dis 1969; 1: 3137.
  • 94
    Graffelman AW, Knuistingh NA, le CS, Kroes AC, Springer MP, van den Broek PJ. A diagnostic rule for the aetiology of lower respiratory tract infections as guidance for antimicrobial treatment. Br J Gen Pract 2004; 54: 2024.
  • 95
    Holm A, Nexoe J, Bistrup LA et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57: 547554.
  • 96
    Hopstaken RM, Coenen S, Butler CC. Treating patients not diagnoses: challenging assumptions underlying the investigation and management of LRTI in general practice. J Antimicrob Chemother 2005; 56: 941943.
  • 97
    Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511514.
  • 98
    Macfarlane J, Holmes W, Gard P et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001; 56: 109114.
  • 99
    Shaw AB, Fry J. Acute infections of the chest in general practice. Br Med J 1955; ii: 15771586.
  • 100
    Almirall J, Morato I, Riera F et al. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993; 6: 1418.
  • 101
    Beovic B, Bonac B, Kese D et al. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 2003; 22: 584591.
  • 102
    Berntsson E, Lagergard T, Strannegard O, Trollfors B. Etiology of community-acquired pneumonia in out-patients. Eur J Clin Microbiol 1986; 5: 446447.
  • 103
    Blanquer J, Blanquer R, Borras R et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991; 46: 508511.
  • 104
    The British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987; 62: 195220.
  • 105
    Dulake C, Selkon J. The incidence of pneumonia in the UK – preliminary findings from Newcastle and London. R Soc Med Int Congr Symp Ser 1989; 27: 8794.
  • 106
    Foy HM, Cooney MK, McMahan R, Grayston JT. Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period. Am J Epidemiol 1973; 97: 93102.
  • 107
    Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99: 6065.
  • 108
    Melbye H, Berdal BP, Straume B, Russell H, Vorland L, Thacker WL. Pneumonia – a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice. Scand J Infect Dis 1992; 24: 647655.
  • 109
    Miyashita N, Fukano H, Mouri K et al. Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. J Med Microbiol 2005; 54 (Pt 4): 395400.
  • 110
    Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1: 671674.
  • 111
    Arancibia F, Bauer TT, Ewig S et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162: 18491858.
  • 112
    Aubertin J, Dabis F, Fleurette J et al. Prevalence of legionellosis among adults: a study of community-acquired pneumonia in France. Infection 1987; 15: 328331.
  • 113
    Ausina V, Coll P, Sambeat M et al. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis 1988; 7: 342347.
  • 114
    Berntsson E, Blomberg J, Lagergard T, Trollfors B. Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol 1985; 4: 268272.
  • 115
    Burman LA, Trollfors B, Andersson B et al. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. J Infect Dis 1991; 163: 10871093.
  • 116
    Charles PG, Whitby M, Fuller AJ et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46: 15131521.
  • 117
    Falco V, Fernandez dS, Alegre J, Ferrer A, Martinez Vazquez JM. Legionella pneumophila. A cause of severe community-acquired pneumonia. Chest 1991; 100: 10071011.
  • 118
    Falguera M, Pifarre R, Martin A, Sheikh A, Moreno A. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest 2005; 128: 32333239.
  • 119
    Garbino J, Sommer R, Gerber A et al. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. Int J Infect Dis 2002; 6: 288293.
  • 120
    Gutierrez F, Masia M, Rodriguez JC et al. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005; 11: 788800.
  • 121
    Holmberg H. Aetiology of community-acquired pneumonia in hospital treated patients. Scand J Infect Dis 1987; 19: 491501.
  • 122
    Hone R, Haugh C, O’Connor B, Hollingsworth J. Legionella: an infrequent cause of adult community acquired pneumonia in Dublin. Ir J Med Sci 1989; 158: 230232.
  • 123
    Huang HH, Zhang YY, Xiu QY et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis 2006; 25: 369374.
  • 124
    Leesik H, Ani U, Juhani A, Altraja A. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia. Medicina (Kaunas) 2006; 42: 384394.
  • 125
    Levy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988; 93: 4348.
  • 126
    Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet 1982; 2: 255258.
  • 127
    Marrie TJ, Peeling RW, Reid T, De CE. Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J 2003; 21: 779784.
  • 128
    McNabb WR, Shanson DC, Williams TD, Lant AF. Adult community-acquired pneumonia in central London. J R Soc Med 1984; 77: 550555.
  • 129
    Ortqvist A, Hedlund J, Grillner L et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990; 3: 11051113.
  • 130
    Ostergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest 1993; 104: 14001407.
  • 131
    Pareja A, Bernal C, Leyva A, Piedrola G, Maroto MC. Etiologic study of patients with community-acquired pneumonia. Chest 1992; 101: 12071210.
  • 132
    Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle HD. The incidence of legionella pneumonia: a 1-year prospective study in a large community hospital. Lung 1989; 167: 1122.
  • 133
    Schneeberger PM, Dorigo-Zetsma JW, van der ZA, van BM, van Opstal JL. Diagnosis of atypical pathogens in patients hospitalized with community-acquired respiratory infection. Scand J Infect Dis 2004; 36: 269273.
  • 134
    Sohn JW, Park SC, Choi YH et al. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci 2006; 21: 602607.
  • 135
    White RJ, Blainey AD, Harrison KJ, Clarke SK. Causes of pneumonia presenting to a district general hospital. Thorax 1981; 36: 566570.
  • 136
    Alkhayer M, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. Respir Med 1990; 84: 1316.
  • 137
    Almirall J, Mesalles E, Klamburg J, Parra O, Agudo A. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995; 107: 511516.
  • 138
    The British Thoracic Society Research Committee and The Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992; 86: 713.
  • 139
    Leroy O, Santre C, Beuscart C et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21: 2431.
  • 140
    Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994; 105: 14871495.
  • 141
    Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985; 17: 377386.
  • 142
    Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990; 142: 369373.
  • 143
    Paganin F, Lilienthal F, Bourdin A et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24: 779785.
  • 144
    Rello J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest 1993; 103: 232235.
  • 145
    Rello J, Bodi M, Mariscal D et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: 174180.
  • 146
    Sorensen J, Forsberg P, Hakanson E et al. A new diagnostic approach to the patient with severe pneumonia. Scand J Infect Dis 1989; 21: 3341.
  • 147
    Torres A, Serra-Batlles J, Ferrer A et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312318.
  • 148
    Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985; 10: 204210.
  • 149
    Fernandez-Sabe N, Carratala J, Roson B et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003; 82: 159169.
  • 150
    Riquelme R, Torres A, El-Ebiary M et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 14501455.
  • 151
    Zalacain R, Torres A, Celis R et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J 2003; 21: 294302.
  • 152
    Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144: 14081410.
  • 153
    Carilli AD, Gohd RS, Gordon W. A virologic study of chronic bronchitis. N Engl J Med 1964; 270: 123127.
  • 154
    Eadie MB, Stott EJ, Grist NR. Virologic studies in chronic bronchitis. Br Med J 1966; 2: 671673.
  • 155
    Erkan L, Uzun O, Findik S, Katar D, Sanic A, Atici AG. Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 463467.
  • 156
    Fagon JY, Chastre J, Trouillet JL et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 10041008.
  • 157
    Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 2003; 97: 770777.
  • 158
    Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465474.
  • 159
    Karnak D, Beng-sun S, Beder S, Kayacan O. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir Med 2001; 95: 811816.
  • 160
    Ko FW, Ng TK, Li TS et al. Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong. Respir Med 2005; 99: 454460.
  • 161
    Lamy ME, Pouthier-Simon F, Debacker-Willame E. Respiratory viral infections in hospital patients with chronic bronchitis. Observations during periods of exacerbation and quiescence. Chest 1973; 63: 336341.
  • 162
    Lieberman D, Ben Yaakov M, Lazarovich Z, Ohana B, Boldur I. Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: analysis of 250 hospitalizations. Eur J Clin Microbiol Infect Dis 2001; 20: 698704.
  • 163
    McNamara MJ, Phillips IA, Williams OB. Viral and Mycoplasma pneumoniae infections in exacerbations of chronic lung disease. Am Rev Respir Dis 1969; 100: 1924.
  • 164
    Mogulkoc N, Karakurt S, Isalska B et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349353.
  • 165
    Monso E, Ruiz J, Rosell A et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152 (4 Pt 1): 13161320.
  • 166
    Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172: 195199.
  • 167
    Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 11141121.
  • 168
    Rohde G, Wiethege A, Borg I et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58: 3742.
  • 169
    Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891897.
  • 170
    Ross CA, McMichael S, Eadie MB, Lees AW, Murray EA, Pinkerton I. Infective agents and chronic bronchitis. Thorax 1966; 21: 461464.
  • 171
    Seemungal T, Harper-Owen R, Bhowmik A et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 16181623.
  • 172
    De SG, Lampron N, La FJ et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46: 129133.
  • 173
    Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 14981505.
  • 174
    Chan TH, Ho SS, Lai CK et al. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chemotherapy 1996; 42: 150156.
  • 175
    King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007; 101: 16331638.
  • 176
    Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995; 108: 955961.
  • 177
    O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 13291334.
  • 178
    Spratt BG, Pardee AB. Penicillin-binding proteins and cell shape in E. coli. Nature 1975; 254: 516517.
  • 179
    Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E. Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother 1999; 43: 14801483.
  • 180
    Carratala J, Marron A, Fernandez-Sevilla A, Linares J, Gudiol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1997; 24: 148152.
  • 181
    Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230237.
  • 182
    Borg MA, Tiemersma E, Scicluna E et al. Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect 2009; 15: 232237.
  • 183
    Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 10161027.
  • 184
    Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Linares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 2009; 64: 507510.
  • 185
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
  • 186
    Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42: 224233.
  • 187
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Int J Antimicrob Agents 2005; 25: 110119.
  • 188
    Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39: 577585.
  • 189
    Syrogiannopoulos GA, Grivea IN, Tait-Kamradt A et al. Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother 2001; 45: 342344.
  • 190
    Johnston NJ, De Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 24252426.
  • 191
    Farrell DJ, Douthwaite S, Morrissey I et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 2003; 47: 17771783.
  • 192
    Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556564.
  • 193
    Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43: 432438.
  • 194
    Doern GV. Macrolide and ketolide resistance with Streptococcus pneumoniae. Med Clin North Am 2006; 90: 11091124.
  • 195
    Anderson R, Steel HC, Cockeran R et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007; 60: 11551158.
  • 196
    Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 23212326.
  • 197
    Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433438.
  • 198
    de la Campa AG, Ardanuy C, Balsalobre L et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis 2009; 15: 905911.
  • 199
    Farrell DJ, Felmingham D, Shackcloth J et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 2008; 62 (suppl 2): ii87ii95.
  • 200
    Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother 2006; 58: 873877.
  • 201
    Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003; 47: 10171022.
  • 202
    Morrissey I, Maher K, Williams L, Shackcloth J, Felmingham D, Reynolds R. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999–2007. J Antimicrob Chemother 2008; 62 (suppl 2): ii97ii103.
  • 203
    Kofteridis DP, Notas G, Maraki S et al. Antimicrobial susceptibilities of 930 Haemophilus influenzae clinical strains isolated from the island of Crete, Greece. Chemotherapy 2008; 54: 492498.
  • 204
    Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005–2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007; 51: 43824389.
  • 205
    Waites KB, Crabb DM, Bing X, Duffy LB. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003; 47: 161165.
  • 206
    Waites KB, Crabb DM, Duffy LB. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob Agents Chemother 2003; 47: 3942.
  • 207
    Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17: 697728, table.
  • 208
    Matsuoka M, Narita M, Okazaki N et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004; 48: 46244630.
  • 209
    Morozumi M, Hasegawa K, Kobayashi R et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother 2005; 49: 23022306.
  • 210
    Morozumi M, Iwata S, Hasegawa K et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008; 52: 348350.
  • 211
    Dumke R, von BH, Luck PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010; 16: 613616.
  • 212
    Peuchant O, Menard A, Renaudin H et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64: 5258.
  • 213
    Stralin K, Soderquist B. Staphylococcus aureus in community-acquired pneumonia. Chest 2006; 130: 623.
  • 214
    Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198: 962970.
  • 215
    Nathwani D, Morgan M, Masterton RG et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008; 61: 976994.
  • 216
    Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 15901597.
  • 217
    Hutschala D, Skhirtladze K, Zuckermann A et al. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chemother 2005; 49: 51075111.
  • 218
    Conte JE Jr, Golden JA, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents 2007; 30: 422427.
  • 219
    Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 62: 99101.
  • 220
    Aspromonte N, Feola M, Scardovi AB et al. Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography. J Cardiovasc Med (Hagerstown) 2006; 7: 406413.
  • 221
    Mikkelsen KV, Bie P, Moller JE, Videbaek L, Villadsen HD, Haghfelt T. Neurohormonal activation and diagnostic value of cardiac peptides in patients with suspected mild heart failure. Int J Cardiol 2006; 110: 324333.
  • 222
    Fuat A, Murphy JJ, Hungin AP et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006; 56: 327333.
  • 223
    Van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002; 324: 1370.
  • 224
    Broekhuizen BD, Sachs AP, Oostvogels R, Hoes AW, Verheij TJ, Moons KG. The diagnostic value of history and physical examination for COPD in suspected or known cases: a systematic review. Fam Pract 2009; 26: 260268.
  • 225
    Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract 2003; 53: 358364.
  • 226
    Graffelman AW, le Cessie S, Knuistingh NA, Wilemssen FE, Zonderland HM, van den Broek PJ. Can history and exam alone reliably predict pneumonia? J Fam Pract 2007; 56: 465470.
  • 227
    Flanders SA, Stein J, Shochat G et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004; 116: 529535.
  • 228
    Holm A, Pedersen SS, Nexoe J et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57: 555560.
  • 229
    van der Meer MV, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331: 26.
  • 230
    Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. Fam Pract 2009; 26: 1021.
  • 231
    Hak E, Bont J, Hoes AW, Verheij TJ. Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract 2005; 22: 375380.
  • 232
    Seppa Y, Bloigu A, Honkanen PO, Miettinen L, Syrjala H. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Arch Intern Med 2001; 161: 27092713.
  • 233
    Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260: 93101.
  • 234
    Bont J, Hak E, Hoes AW, Schipper M, Schellevis FG, Verheij TJ. A prediction rule for elderly primary-care patients with lower respiratory tract infections. Eur Respir J 2007; 29: 969975.
  • 235
    Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med 2008; 168: 14651468.
  • 236
    Bont J. Lower respiratory tract infections in the elderly; prognostic studies in primary care. Utrecht, The Netherlands: University Medical Center Utrecht, 2008.
  • 237
    Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Chichester, UK: John Wiley & Sons, Ltd., 2010.
  • 238
    Smucny J, Becker LA, Glazier R. Beta2-agonists for acute bronchitis. Chichester, UK: John Wiley & Sons, Ltd., 2010.
  • 239
    Ponsioen BP, Hop WC, Vermue NA, Dekhuijzen PN, Bohnen AM. Efficacy of fluticasone on cough: a randomised controlled trial. Eur Respir J 2005; 25: 147152.
  • 240
    Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Chichester, UK: John Wiley & Sons, Ltd, 2010.
  • 241
    Little P, Rumsby K, Kelly J et al. Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial. JAMA 2005; 293: 30293035.
  • 242
    Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD004403.
  • 243
    Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2004; 2: CD002109.
  • 244
    Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330: 456.
  • 245
    Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326: 1235.
  • 246
    Jefferson T, Demicheli V, Rivetti D, Jones M, Di PC, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367: 30313.
  • 247
    Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377382.
  • 248
    Ewig S, de RA, Bauer T et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004; 59: 421427.
  • 249
    Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 10621069.
  • 250
    Aujesky D, McCausland JB, Whittle J, Obrosky DS, Yealy DM, Fine MJ. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis 2009; 49: e100e108.
  • 251
    Capelastegui A, Espana PP, Quintana JM et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27: 151157.
  • 252
    Buising KL, Thursky KA, Black JF et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006; 61: 419424.
  • 253
    Man SY, Lee N, Ip M et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007; 62: 348353.
  • 254
    Myint PK, Kamath AV, Vowler SL, Maisey DN, Harrison BD. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts. Age Ageing 2006; 35: 286291.
  • 255
    Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007; 62: 253259.
  • 256
    Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax 2008; 63: 698702.
  • 257
    Labarere J, Stone RA, Scott OD et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med 2006; 21: 745752.
  • 258
    Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J 2007; 14: 212216.
  • 259
    Seymann G, Barger K, Choo S, Sawhney S, Davis D. Clinical judgment versus the Pneumonia Severity Index in making the admission decision. J Emerg Med 2008; 34: 261268.
  • 260
    Loeb M, Carusone SC, Goeree R et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295: 25032510.
  • 261
    Hirakata Y, Yanagihara K, Kurihara S et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 170174.
  • 262
    Hohenthal U, Hurme S, Helenius H et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect 2009; 15: 10261032.
  • 263
    Menendez R, Martinez R, Reyes S et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587591.
  • 264
    Thiem U, Niklaus D, Sehlhoff B et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age Ageing 2009; 38: 693697.
  • 265
    Okimoto N, Hayashi Y, Ishiga M et al. Procalcitonin and severity of community-acquired pneumonia. J Infect Chemother 2009; 15: 426427.
  • 266
    Kruger S, Papassotiriou J, Marre R et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 2007; 33: 20692078.
  • 267
    Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med 2009; 53: 633638.
  • 268
    Kruger S, Ewig S, Kunde J et al. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia – influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. J Antimicrob Chemother 2009; 64: 159162.
  • 269
    Christ-Crain M, Breidthardt T, Stolz D et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008; 264: 166176.
  • 270
    Prat C, Lacoma A, Dominguez J et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007; 55: 400407.
  • 271
    Christ-Crain M, Morgenthaler NG, Stolz D et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96.
  • 272
    Huang DT, Angus DC, Kellum JA et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823831.
  • 273
    Tejera A, Santolaria F, Diez ML et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 2007; 38: 117123.
  • 274
    Christ-Crain M, Stolz D, Jutla S et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176: 913920.
  • 275
    Salluh JI, Bozza FA, Soares M et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest 2008; 134: 947954.
  • 276
    Kruger S, Ewig S, Marre R et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349355.
  • 277
    Huang DT, Weissfeld LA, Kellum JA et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52: 4858.
  • 278
    Phua J, See KC, Chan YH et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009; 64: 598603.
  • 279
    Charles PG, Wolfe R, Whitby M et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375384.
  • 280
    Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis 2008; 47: 15711574.
  • 281
    Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009; 37: 30103016.
  • 282
    Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007; 86: 103111.
  • 283
    Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004; 32: 23982402.
  • 284
    Renaud B, Santin A, Coma E et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37: 28672874.
  • 285
    Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32: 726732.
  • 286
    Wu CL, Lin FJ, Lee SY et al. Early evolution of arterial oxygenation in severe community-acquired pneumonia: a prospective observational study. J Crit Care 2007; 22: 129136.
  • 287
    Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11: 586599.
  • 288
    Gleckman R, DeVita J, Hibert D, Pelletier C, Martin R. Sputum gram stain assessment in community-acquired bacteremic pneumonia. J Clin Microbiol 1988; 26: 846849.
  • 289
    Benenson RS, Kepner AM, Pyle DN, Cavanaugh S. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007; 33: 18.
  • 290
    Afshar N, Tabas J, Afshar K, Silbergleit R. Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review. J Hosp Med 2009; 4: 112123.
  • 291
    Bradley SF. Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 2005; 26: 643649.
  • 292
    El Solh AA, Akinnusi ME, Pineda LA, Mankowski CR. Diagnostic yield of quantitative endotracheal aspirates in patients with severe nursing home-acquired pneumonia. Crit Care 2007; 11: R57.
  • 293
    Lagerstrom F, Fredlund H, Holmberg H. Sputum specimens can be obtained from patients with community-acquired pneumonia in primary care. Scand J Prim Health Care 2004; 22: 8386.
  • 294
    Garcia-Vazquez E, Marcos MA, Mensa J et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164: 18071811.
  • 295
    van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Jansen HM, Boersma WG. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241249.
  • 296
    Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39: 165169.
  • 297
    Signori LG, Ferreira MW, Vieira LC, Muller KR, Mattos WL. Sputum examination in the clinical management of community-acquired pneumonia. J Bras Pneumol 2008; 34: 152158.
  • 298
    Anevlavis S, Petroglou N, Tzavaras A et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009; 59: 8389.
  • 299
    Uffredi ML, Mangiapan G, Cadranel J, Kac G. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003; 22: 457462.
  • 300
    Ortega L, Sierra M, Dominguez J et al. Utility of a pneumonia severity index in the optimization of the diagnostic and therapeutic effort for community-acquired pneumonia. Scand J Infect Dis 2005; 37: 657663.
  • 301
    Gutierrez F, Masia M, Rodriguez JC et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36: 286292.
  • 302
    Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 14951502.
  • 303
    Marcos MA, Jimenez de Anta MT, de la Bellacasa JP et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003; 21: 209214.
  • 304
    Roson B, Fernandez-Sabe N, Carratala J et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38: 222226.
  • 305
    Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. J Infect Chemother 2004; 10: 359363.
  • 306
    Stralin K, Kaltoft MS, Konradsen HB, Olcen P, Holmberg H. Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. J Clin Microbiol 2004; 42: 36203625.
  • 307
    Andreo F, Dominguez J, Ruiz-Manzano J et al. Usefulness of pneumococcal antigen detection in pleural fluid samples by immunochromatographic assay for diagnosis of pneumococcal pneumonia. Clin Microbiol Infect 2006; 12: 682684.
  • 308
    Ercis S, Ergin A, Sahin GO, Hascelik G, Uzun O. Validation of urinary antigen test for Streptococcus pneumoniae in patients with pneumococcal pneumonia. Jpn J Infect Dis 2006; 59: 388390.
  • 309
    Genne D, Sommer R, Kaiser L et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 159166.
  • 310
    Lasocki S, Scanvic A, Le TF et al. Evaluation of the Binax NOW Streptococcus pneumoniae urinary antigen assay in intensive care patients hospitalized for pneumonia. Intensive Care Med 2006; 32: 17661772.
  • 311
    Leeming JP, Cartwright K, Morris R, Martin SA, Smith MD. Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection. J Clin Microbiol 2005; 43: 49724976.
  • 312
    Kobashi Y, Yoshida K, Miyashita N, Niki Y, Matsushima T. Evaluating the use of a Streptococcus pneumoniae urinary antigen detection kit for the management of community-acquired pneumonia in Japan. Respiration 2007; 74: 387393.
  • 313
    Oka H, Ueda A, Watanuki Y et al. The efficacy of high-dose penicillin for community-acquired pneumonia diagnosed by pneumococcal urine antigen test. J Infect Chemother 2009; 15: 108112.
  • 314
    Smith MD, Sheppard CL, Hogan A et al. Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. J Clin Microbiol 2009; 47: 10461049.
  • 315
    Andreo F, Prat C, Ruiz-Manzano J et al. Persistence of Streptococcus pneumoniae urinary antigen excretion after pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 197201.
  • 316
    Korsgaard J, Moller JK, Kilian M. Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults. Int J Infect Dis 2005; 9: 274279.
  • 317
    Dominguez J, Andreo F, Blanco S et al. Rapid detection of pneumococcal antigen in serum samples for diagnosing pneumococcal pneumonia. J Infect 2006; 53: 2124.
  • 318
    Porcel JM, Ruiz-Gonzalez A, Falguera M et al. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. Chest 2007; 131: 14421447.
  • 319
    Dirven K, Ieven M, Peeters MF, van der ZA, De SK, Goossens H. Comparison of three Legionella urinary antigen assays during an outbreak of legionellosis in Belgium. J Med Microbiol 2005; 54 (Pt 12): 12131216.
  • 320
    Guerrero C, Toldos CM, Yague G, Ramirez C, Rodriguez T, Segovia M. Comparison of diagnostic sensitivities of three assays (Bartels enzyme immunoassay [EIA], Biotest EIA, and Binax NOW immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine. J Clin Microbiol 2004; 42: 467468.
  • 321
    Olsen CW, Elverdal P, Jorgensen CS, Uldum SA. Comparison of the sensitivity of the Legionella urinary antigen EIA kits from Binax and Biotest with urine from patients with infections caused by less common serogroups and subgroups of Legionella. Eur J Clin Microbiol Infect Dis 2009; 28: 817820.
  • 322
    Blanco S, Lacoma A, Prat C et al. Detection of Legionella antigen in nonconcentrated and concentrated urine samples by a new immunochromatographic assay. Eur J Clin Microbiol Infect Dis 2008; 27: 12491251.
  • 323
    Diederen BM, Bruin JP, Scopes E, Peeters MF, IJzerman EP. Evaluation of the Oxoid Xpect Legionella test kit for detection of Legionella pneumophila serogroup 1 antigen in urine. J Clin Microbiol 2009; 47: 22722274.
  • 324
    Alvarez J, Dominguez A, Sabria M et al. Impact of the Legionella urinary antigen test on epidemiological trends in community outbreaks of legionellosis in Catalonia, Spain, 1990–2004. Int J Infect Dis 2009; 13: e365e370.
  • 325
    Blazquez RM, Espinosa FJ, Martinez-Toldos CM, Alemany L, Garcia-Orenes MC, Segovia M. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 488491.
  • 326
    von BH, Ewig S, Marre R et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008; 46: 13561364.
  • 327
    Steininger C, Redlberger M, Graninger W, Kundi M, Popow-Kraupp T. Near-patient assays for diagnosis of influenza virus infection in adult patients. Clin Microbiol Infect 2009; 15: 267273.
  • 328
    Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007; 28: 171181.
  • 329
    Vazquez EG, Marcos MA, Vilella A, Yague J, Bayas JM, Mensa J. Assessment of a commercial rapid urinary antigen test to detect Streptococcus pneumoniae in patients who received 23-valent pneumococcal polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 2004; 23: 927929.
  • 330
    Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard”. J Clin Microbiol 2005; 43: 22772285.
  • 331
    Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2004; 11: 862867.
  • 332
    Nir-Paz R, Michael-Gayego A, Ron M, Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin Microbiol Infect 2006; 12: 685688.
  • 333
    Templeton KE, Scheltinga SA, Graffelman AW et al. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J Clin Microbiol 2003; 41: 43664371.
  • 334
    Martinez MA, Ruiz M, Zunino E, Luchsinger V, Avendano LF. Detection of Mycoplasma pneumoniae in adult community-acquired pneumonia by PCR and serology. J Med Microbiol 2008; 57 (Pt 12): 14911495.
  • 335
    von BH, Welte T, Marre R, Suttorp N, Luck C, Ewig S. Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis 2009; 9: 62.
  • 336
    Hvidsten D, Halvorsen DS, Berdal BP, Gutteberg TJ. Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling. Clin Microbiol Infect 2009; 15: 4249.
  • 337
    Elverdal P, Jorgensen CS, Uldum SA. Comparison and evaluation of four commercial kits relative to an in-house immunofluorescence test for detection of antibodies against Legionella pneumophila. Eur J Clin Microbiol Infect Dis 2008; 27: 149152.
  • 338
    Johansson N, Kalin M, Giske CG, Hedlund J. Quantitative detection of Streptococcus pneumoniae from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 60: 255261.
  • 339
    Abdeldaim G, Herrmann B, Molling P et al. Usefulness of real-time PCR for lytA, ply, and Spn9802 on plasma samples for the diagnosis of pneumococcal pneumonia. Clin Microbiol Infect 2010; 16: 11351141.
  • 340
    Peters RP, de Boer RF, Schuurman T et al. Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. J Clin Microbiol 2009; 47: 33083312.
  • 341
    Rello J, Lisboa T, Lujan M et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136: 832840.
  • 342
    Abdeldaim GM, Stralin K, Kirsebom LA, Olcen P, Blomberg J, Herrmann B. Detection of Haemophilus influenzae in respiratory secretions from pneumonia patients by quantitative real-time polymerase chain reaction. Diagn Microbiol Infect Dis 2009; 64: 366373.
  • 343
    Maurin M, Hammer L, Gestin B et al. Quantitative real-time PCR tests for diagnostic and prognostic purposes in cases of legionellosis. Clin Microbiol Infect 2010; 16: 379384.
  • 344
    Raty R, Ronkko E, Kleemola M. Sample type is crucial to the diagnosis of Mycoplasma pneumoniae pneumonia by PCR. J Med Microbiol 2005; 54 (Pt 3): 287291.
  • 345
    Diederen BM, Kluytmans JA, Vandenbroucke-Grauls CM, Peeters MF. Utility of real-time PCR for diagnosis of Legionnaires’ disease in routine clinical practice. J Clin Microbiol 2008; 46: 671677.
  • 346
    Nilsson AC, Bjorkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol 2008; 8: 93.
  • 347
    Thurman KA, Walter ND, Schwartz SB et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis 2009; 48: 12441249.
  • 348
    Andre P, Caro V, Njamkepo E, Wendelboe AM, Van RA, Guiso N. Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007. J Clin Microbiol 2008; 46: 16721677.
  • 349
    Sotir MJ, Cappozzo DL, Warshauer DM et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis 2007; 44: 12161219.
  • 350
    Mahony J, Chong S, Merante F et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol 2007; 45: 29652970.
  • 351
    van de Pol AC, van Loon AM, Wolfs TF et al. Increased detection of respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses with real-time PCR in samples from patients with respiratory symptoms. J Clin Microbiol 2007; 45: 22602262.
  • 352
    Ginocchio CC, Zhang F, Manji R et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol 2009; 45: 191195.
  • 353
    Caram LB, Chen J, Taggart EW et al. Respiratory syncytial virus outbreak in a long-term care facility detected using reverse transcriptase polymerase chain reaction: an argument for real-time detection methods. J Am Geriatr Soc 2009; 57: 482485.
  • 354
    Berjohn CM, Fishman NO, Joffe MM, Edelstein PH, Metlay JP. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. Medicine (Baltimore) 2008; 87: 160166.
  • 355
    Cheng AC, Buising KL. Delayed administration of antibiotics and mortality in patients with community-acquired pneumonia 89. Ann Emerg Med 2009; 53: 618624.
  • 356
    Bruns AH, Oosterheert JJ, Hustinx WN, Gaillard CA, Hak E, Hoepelman AI. Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 913919.
  • 357
    Fee C, Weber EJ. Identification of 90% of patients ultimately diagnosed with community-acquired pneumonia within four hours of emergency department arrival may not be feasible. Ann Emerg Med 2007; 49: 553559.
  • 358
    Friedberg MW, Mehrotra A, Linder JA. Reporting hospitals’ antibiotic timing in pneumonia: adverse consequences for patients? Am J Manag Care 2009; 15: 137144.
  • 359
    Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007; 131: 18651869.
  • 360
    Pines JM, Isserman JA, Hinfey PB. The measurement of time to first antibiotic dose for pneumonia in the emergency department: a white paper and position statement prepared for the American Academy of Emergency Medicine. J Emerg Med 2009; 37: 335340.
  • 361
    Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother 2007; 19: 536545.
  • 362
    Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 2004; 24: 95104.
  • 363
    Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51: 39773982.
  • 364
    Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131: 466473.
  • 365
    Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009; 63: 10251033.
  • 366
    Paul M, Nielsen AD, Gafter-Gvili A et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 2007; 30: 525531.
  • 367
    File TM Jr. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. Int J Antimicrob Agents 2007; 30 (suppl 2): S131S134.
  • 368
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002; 20: 119129.
  • 369
    Siquier B, Sanchez-Alvarez J, Garcia-Mendez E et al. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006; 57: 536545.
  • 370
    Dartois N, Castaing N, Gandjini H, Cooper A. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008; 20 (suppl 1): 2835.
  • 371
    Lin TY, Lin SM, Chen HC et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007; 30: 321332.
  • 372
    Portier H, Brambilla C, Garre M, Paganin F, Poubeau P, Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24: 367376.
  • 373
    Querol-Ribelles JM, Tenias JM, Querol-Borras JM et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005; 25: 7583.
  • 374
    Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002; 36: 19381943.
  • 375
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin 2008; 24: 895906.
  • 376
    Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia 509. Diagn Microbiol Infect Dis 2008; 61: 329338.
  • 377
    Tanaseanu C, Milutinovic S, Calistru PI et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009; 9: 44.
  • 378
    Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 135143.
  • 379
    Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 12691277.
  • 380
    Van BF, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359378.
  • 381
    Bergallo C, Jasovich A, Teglia O et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63: 5261.
  • 382
    Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53 (suppl 2): ii59ii66.
  • 383
    Vetter N, Cambronero-Hernandez E, Rohlf J et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24: 17701785.
  • 384
    Yakovlev SV, Stratchounski LS, Woods GL et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis 2006; 25: 633641.
  • 385
    Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139146.
  • 386
    Murcia JM, Gonzalez-Comeche J, Marin A et al. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clin Microbiol Infect 2009; 15: 10461050.
  • 387
    Paladino JA, Eubanks DA, Adelman MH, Schentag JJ. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia. J Am Geriatr Soc 2007; 55: 651657.
  • 388
    von BH, Welte T, Marre R, Suttorp N, Ewig S. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J 2010; 35: 598605.
  • 389
    Frei CR, Koeller JM, Burgess DS, Talbert RL, Johnsrud MT. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy 2003; 23: 11671174.
  • 390
    Lui G, Ip M, Lee N et al. Role of ‘atypical pathogens’ among adult hospitalized patients with community-acquired pneumonia. Respirology 2009; 14: 10981105.
  • 391
    Shefet D, Robenshtock E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2005; 2: CD004418.
  • 392
    Garcia VE, Mensa J, Martinez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24: 190195.
  • 393
    Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004; 38 (suppl 4): S328S340.
  • 394
    Weiss K, Low DE, Cortes L et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 589593.
  • 395
    Alvarez LF. Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients. J Chemother 2004; 16 (suppl 2): 1517.
  • 396
    Erard V, Lamy O, Bochud PY, Bille J, Cometta A, Calandra T. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2004; 23: 8288.
  • 397
    Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004; 27: 395405.
  • 398
    Lode H, Grossman C, Choudhri S et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003; 97: 11341142.
  • 399
    Rodriguez A, Mendia A, Sirvent JM et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 14931498.
  • 400
    Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46: 14991509.
  • 401
    Wasserfallen JB, Erard V, Cometta A, Calandra T, Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 2004; 24: 644648.
  • 402
    Romanelli G, Cravarezza P, Pozzi A et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J Chemother 2002; 14: 609617.
  • 403
    File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48: 33233331.
  • 404
    Martinez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389395.
  • 405
    Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005; 128: 940946.
  • 406
    Aspa J, Rajas O, Rodriguez de CF et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004; 38: 787798.
  • 407
    Bonnard P, Lescure FX, Douadi Y et al. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome. J Infect 2005; 51: 6976.
  • 408
    Falco V, Almirante B, Jordano Q et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J Antimicrob Chemother 2004; 54: 481488.
  • 409
    Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004; 32: 625631.
  • 410
    Plouffe JF, Breiman RF, Fields BS et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003; 37: 14751480.
  • 411
    Sabria M, Pedro-Botet ML, Gomez J et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128: 14011405.
  • 412
    Yu VL, Greenberg RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 21352139.
  • 413
    Capelastegui A, Espana PP, Quintana JM et al. Declining length of hospital stay for pneumonia and postdischarge outcomes. Am J Med 2008; 121: 845852.
  • 414
    Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008; 46: 550556.
  • 415
    Yende S, D’Angelo G, Kellum JA et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177: 12421247.
  • 416
    Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 25882598.
  • 417
    Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 8493.
  • 418
    Kristoffersen KB, Sogaard OS, Wejse C et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission – a randomized trial. Clin Microbiol Infect 2009; 15: 481487.
  • 419
    Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 10591066.
  • 420
    Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463474.
  • 421
    Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498505.
  • 422
    El Moussaoui MR, de Borgie CA, van den BP et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332: 1355.
  • 423
    Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 2008; 68: 24692481.
  • 424
    Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007; 12: 111116.
  • 425
    Marras TK, Nopmaneejumruslers C, Chan CK. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. Am J Med 2004; 116: 385393.
  • 426
    van der Eerden MM, de Graaff CS, Vlaspolder F, Bronsveld W, Jansen HM, Boersma WG. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia. Clin Ther 2004; 26: 294303.
  • 427
    Shindo Y, Sato S, Maruyama E et al. Implication of clinical pathway care for community-acquired pneumonia in a community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone. Intern Med 2008; 47: 18651874.
  • 428
    Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119: 512517.
  • 429
    Oosterheert JJ, Bonten MJ, Schneider MM et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333: 1193.
  • 430
    Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124: 883889.
  • 431
    Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto MG. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160 (5 Pt 1): 15851591.
  • 432
    Ferrer M, Esquinas A, Leon M, Gonzalez G, Alarcon A, Torres A. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 14381444.
  • 433
    Antonelli M, Conti G, Esquinas A et al. A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. Crit Care Med 2007; 35: 1825.
  • 434
    Bulow HH, Thorsager B. Non-invasive ventilation in do-not-intubate patients: five-year follow-up on a two-year prospective, consecutive cohort study. Acta Anaesthesiol Scand 2009; 53: 11531157.
  • 435
    Confalonieri M, Urbino R, Potena A et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242248.
  • 436
    Gorman SK, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007; 41: 12331237.
  • 437
    Salluh JI, Povoa P, Soares M, Castro-Faria-Neto HC, Bozza FA, Bozza PT. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008; 12: R76.
  • 438
    Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008; 62: 661668.
  • 439
    Adams R, Ruffin R, Campbell D. The value of the lipid-laden macrophage index in the assessment of aspiration pneumonia. Aust N Z J Med 1997; 27: 550553.
  • 440
    Chen JH, Lamberg JL, Chen YC et al. Occurrence and treatment of suspected pneumonia in long-term care residents dying with advanced dementia. J Am Geriatr Soc 2006; 54: 290295.
  • 441
    DeToledo JC, Lowe MR, Gonzalez J, Haddad H. Risk of aspiration pneumonia after an epileptic seizure: a retrospective analysis of 1634 adult patients. Epilepsy Behav 2004; 5: 593595.
  • 442
    Kadowaki M, Demura Y, Mizuno S et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 2005; 127: 12761282.
  • 443
    Mier L, Dreyfuss D, Darchy B et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993; 19: 279284.
  • 444
    Mylotte JM, Goodnough S, Naughton BJ. Pneumonia versus aspiration pneumonitis in nursing home residents: diagnosis and management. J Am Geriatr Soc 2003; 51: 1723.
  • 445
    Reza SM, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc 2006; 54: 296302.
  • 446
    Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T. High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc 2008; 56: 577579.
  • 447
    Allewelt M, Schuler P, Bolcskei PL, Mauch H, Lode H. Ampicillin + sulbactam vs clindamycin +/− cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 2004; 10: 163170.
  • 448
    Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess. Penicillin G vs clindamycin. JAMA 1975; 234: 935937.
  • 449
    Fernandez-Sabe N, Carratala J, Dorca J et al. Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections. Eur J Clin Microbiol Infect Dis 2003; 22: 185187.
  • 450
    Gudiol F, Manresa F, Pallares R et al. Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990; 150: 25252529.
  • 451
    Perlino CA. Metronidazole vs clindamycin treatment of anerobic pulmonary infection. Failure of metronidazole therapy. Arch Intern Med 1981; 141: 14241427.
  • 452
    Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36: 2330.
  • 453
    Chen CZ, Fan PS, Lin CC, Lee CH, Hsiue TR. Repeated pneumonia severity index measurement after admission increases its predictive value for mortality in severe community-acquired pneumonia. J Formos Med Assoc 2009; 108: 219223.
  • 454
    Menendez R, Cavalcanti M, Reyes S et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63: 447452.
  • 455
    Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219225.
  • 456
    Coelho L, Povoa P, Almeida E et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92.
  • 457
    Lieberman D, Shmarkov O, Gelfer Y, Varshavsky R, Lieberman DV. Prevalence and clinical significance of fever in acute exacerbations of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis 2003; 22: 7578.
  • 458
    Allegra L, Blasi F, Diano P et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005; 99: 742747.
  • 459
    Soler N, Agusti C, Angrill J, Puig DlB, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 2935.
  • 460
    Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009; 103: 601606.
  • 461
    Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007; 55: 226232.
  • 462
    Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 919.
  • 463
    Lieberman D, Lieberman D, Ben-Yaakov M et al. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. Diagn Microbiol Infect Dis 2002; 44: 16.
  • 464
    Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007; 12: 8187.
  • 465
    Montero M, Dominguez M, Orozco-Levi M, Salvado M, Knobel H. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection 2009; 37: 1619.
  • 466
    Lode H, Allewelt M, Balk S et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143149.
  • 467
    Garcia-Vidal C, Almagro P, Romani V et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34: 10721078.
  • 468
    Kahn JB, Khashab M, Ambruzs M. Study entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severity. Curr Med Res Opin 2007; 23: 17.
  • 469
    Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266272.
  • 470
    Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 10901095.
  • 471
    Sethi S, Sethi R, Eschberger K et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356361.
  • 472
    Sethi S, Wrona C, Grant BJ, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448453.
  • 473
    Aaron SD, Kottachchi D, Ferris WJ et al. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 2004; 24: 631637.
  • 474
    Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003; 97: 242249.
  • 475
    Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005; 25: 10011010.
  • 476
    Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132: 447455.
  • 477
    Ferrer M, Ioanas M, Arancibia F, Marco MA, de la Bellacasa JP, Torres A. Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2005; 33: 20032009.
  • 478
    Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 15031510.
  • 479
    Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev 2003; 4: CD001392.
  • 480
    Cogo R, Ramponi A, Scivoletto G, Rippoli R. Prophylaxis for acute exacerbations of chronic bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical and pharmacoeconomic study. Acta Biomed Ateneo Parmense 2003; 74: 8187.
  • 481
    Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev 2003; 3: CD001958.
  • 482
    Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126: 16451655.
  • 483
    Tricarico D, Varricchio A, D’Ambrosio S, Ascione E, Motta G. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial. Arzneimittelforschung 2004; 54: 5763.
  • 484
    Black P, Staykova T, Chacko E, Ram FS, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003; 1: CD004105.
  • 485
    Smucny J, Fahey T, Becker L, Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2004; 4: CD000245.
  • 486
    Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations 86. Am J Respir Crit Care Med 2008; 178: 11391147.
  • 487
    Sethi S, Jones PW, Theron MS et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.
  • 488
    Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39: 3944.
  • 489
    Barker AF, Couch L, Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162 (2Pt1): 481485.
  • 490
    Cymbala AA, Edmonds LC, Bauer MA et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4: 117122.
  • 491
    Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis 232. Respir Med 2008; 102: 14941496.
  • 492
    Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21: 761768.
  • 493
    Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD001287.
  • 494
    Douglas RM, Hemila H, D’Souza R, Chalker EB, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2004; 4: CD000980.
  • 495
    Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA, D’Alessio D. Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 939946.
  • 496
    McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. J Altern Complement Med 2006; 12: 153157.
  • 497
    Heimer KA, Hart AM, Martin LG, Rubio-Wallace S. Examining the evidence for the use of vitamin C in the prophylaxis and treatment of the common cold. J Am Acad Nurse Pract 2009; 21: 295300.
  • 498
    Sjogren P, Nilsson E, Forsell M, Johansson O, Hoogstraate J. A systematic review of the preventive effect of oral hygiene on pneumonia and respiratory tract infection in elderly people in hospitals and nursing homes: effect estimates and methodological quality of randomized controlled trials. J Am Geriatr Soc 2008; 56: 21242130.
  • 499
    Awano S, Ansai T, Takata Y et al. Oral health and mortality risk from pneumonia in the elderly. J Dent Res 2008; 87: 334339.
  • 500
    Bassim CW, Gibson G, Ward T, Paphides BM, Denucci DJ. Modification of the risk of mortality from pneumonia with oral hygiene care. J Am Geriatr Soc 2008; 56: 16011607.
  • 501
    Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219229.
  • 502
    Almirall J, Bolibar I, Serra-Prat M et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008; 31: 12741284.
  • 503
    Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162166.
  • 504
    Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 24072416.
  • 505
    Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712719.
  • 506
    Mortensen EM, Pugh MJ, Copeland LA et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31: 611617.
  • 507
    Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121: 10021007.
  • 508
    Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009; 338: b2137.
  • 509
    Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27: 325332.
  • 510
    Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008; 168: 20812087.
  • 511
    Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 16581667.
  • 512
    Hak E, Buskens E, van Essen GA et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005; 165: 274280.
  • 513
    Hak E, Hoes AW, Grobbee DE et al. Conventional influenza vaccination is not associated with complications in working-age patients with asthma or chronic obstructive pulmonary disease. Am J Epidemiol 2003; 157: 692700.
  • 514
    Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax 2009; 64: 567572.
  • 515
    Ortqvist A, Granath F, Askling J, Hedlund J. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur Respir J 2007; 30: 414422.
  • 516
    Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35: 337344.
  • 517
    Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside “flu” season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178: 527533.
  • 518
    Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study 181. Lancet 2008; 372: 398405.
  • 519
    Jefferson T, Di PC, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2: CD004876.
  • 520
    Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272: 16611665.
  • 521
    Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007; 56 (RR-6): 154.
  • 522
    Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009; 301: 945953.
  • 523
    Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361: 12601267.
  • 524
    Nichol K, D’Heilly S, Ehlinger EP. Influenza vaccination among college and university students: impact on influenzalike illness, health care use, and impaired school performance. Arch Pediatr Adolesc Med 2008; 162: 11131118.
  • 525
    Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; 3: CD001269.
  • 526
    Thomas RE, Jefferson T, Demicheli V, Rivetti D. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2006; 3: CD005187.
  • 527
    Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2010; 2: CD005187.
  • 528
    Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21: 12681274.
  • 529
    van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J 2005; 25: 482489.
  • 530
    Ortqvist A, Henckaerts I, Hedlund J, Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine 2007; 25: 24452450.
  • 531
    Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 2004; 22: 13621371.
  • 532
    Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198: 10191027.
  • 533
    de Roux A, Schmole-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 10151023.
  • 534
    Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354: 14551463.
  • 535
    Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 17371746.
  • 536
    Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 11791186.
  • 537
    Nelson JC, Jackson M, Yu O et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults 211. Vaccine 2008; 26: 49474954.
  • 538
    Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19: 353363.
  • 539
    Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; 4: CD000422.
  • 540
    Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22: 32143224.
  • 541
    Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 1: CD000422.
  • 542
    Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189195.
  • 543
    Jackson LA, Neuzil KM, Yu O et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 17471755.
  • 544
    Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363368.
  • 545
    Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43: 860868.
  • 546
    Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340: c1004.
  • 547
    Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 2008; 5: 52.
  • 548
    Ochoa-Gondar O, Vila-Corcoles A, Ansa X et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008; 26: 19551962.
  • 549
    Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007; 22: 6267.
  • 550
    Skull SA, Andrews RM, Byrnes GB et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 2007; 25: 46314640.
  • 551
    Spindler C, Hedlund J, Jasir A, Normark BH, Ortqvist A. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 2008; 26: 55415546.
  • 552
    Mooney JD, Weir A, McMenamin J et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008; 8: 53.
  • 553
    Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42: 10931101.
  • 554
    Mykietiuk A, Carratala J, Dominguez A et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 457462.
  • 555
    Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004; 19: 365375.
  • 556
    Mangtani P, Roberts JA, Hall AJ, Cutts FT. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol 2005; 34: 565574.
  • 557
    McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A. Pneumococcal pneumonia in the UK – how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 2005; 23: 17391745.
  • 558
    Jackson LA, Neuzil KM, Whitney CG et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005; 23: 36973703.
  • 559
    Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96103.
  • 560
    Waites KB, Canupp KC, Chen YY, DeVivo MJ, Nahm MH. Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine. J Spinal Cord Med 2008; 31: 5359.
  • 561
    Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167: 19381943.
  • 562
    Dexter PR, Perkins SM, Maharry KS, Jones K, McDonald CJ. Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial. JAMA 2004; 292: 23662371.
  • 563
    Jacobson VJ, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst Rev 2005; 3: CD003941.
  • 564
    deHart MP, Salinas SK, Barnette LJ Jr et al. Project protect: pneumococcal vaccination in Washington State nursing homes. J Am Med Dir Assoc 2005; 6: 9196.
  • 565
    Jha AK, Wright SM, Perlin JB. Performance measures, vaccinations, and pneumonia rates among high-risk patients in Veterans Administration health care. Am J Public Health 2007; 97: 21672172.